The report seems to be about what was expected. However, what I'm not crazy about is the Isradipine no longer working out via Mikah on top of the API supply issue. I hope Naltrexone and Phendimetrizine launch soon. I don't expect the PPS to fare well in regard to this quarterly report. Let's hope I'm wrong!